Navigation Links
Consumer Reports 'Best Buy Drug' for Enlarged Prostate Could Save Consumers Nearly $3,000 a Year
Date:6/15/2009

most commonly prescribed drugs in 2008 with 11 million prescriptions written.

"Flomax is just the latest in a series of drugs promoted as blockbusters that, in fact, create more sticker shock than anything else," says Santa. "The advertising appeal to middle aged men capitalizes on something all men want to avoid -- standing in a restroom line at a sporting event. But consumers who are savvy enough to see through these marketing strategies might find themselves with enough money to attend more sporting events rather than buying brand drugs."

Try Lifestyle Changes First; Then Drugs

Almost all men -- if they reach a certain age -- will develop an enlarged prostate, also known as Benign Prostatic Hypertrophy, or BPH. The statistics are not precise, but about half of men of any age who have BPH will have symptoms that require attention and treatment that may involve taking one of the drugs evaluated in the report.

"This means that millions of men over the age of 50 are regularly taking drugs or using other treatment options to ease the symptoms of BPH," says Santa.

Consumer Reports Best Buy Drugs recommends trying lifestyle changes first, which can often provide relief. Those changes include going to the bathroom when you first feel the urge, reducing or eliminating intake of alcohol and caffeine, and limiting fluid intake before bedtime. If these don't bring relief, the next step is usually to consider medication.

JUNE 2009

The material above is intended for legitimate news entities only; it may not be used for commercial or promotional purposes. Consumer Reports(R) is published by Consumers Union, an expert, independent nonprofit organization whose mission is to work for a fair, just, and safe marketplace for all consumers and to empower consumers to protect themselves. To achieve this mission, we test, inform, and protec
'/>"/>

SOURCE Consumer Reports Best Buy Drugs
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. National Survey Reveals a Broken System for Chronic Disease Sufferers; National Council on Aging and Health Experts Explore Self-Care as a Viable, Consumer Focused Option for Health Reform
2. Perrier Refutes Consumer Council Findings
3. National Restaurant Association Backs Bipartisan Senate Agreement to Empower Consumers Nationwide With More Nutrition Information
4. First Brain Training Consumers Guide Debunks Ten Brain Health Myths and Reviews 21 Products
5. Families, Consumers of Home Care Impacted by Budget Cuts to Hold Noon Vigil Outside Fresno Board of Supervisors Meeting as Clock Ticks Down to July 1st Deadline
6. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
7. Consumer Watchdog to Congress: Put Patients Bill of Rights Back on the Table
8. Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study
9. New Health Monitoring and Health Tracking Website, VitalsTracker.com, Helps Health Consumers Organize Important Medical Data
10. Consumer Watchdog Praises Insurance Commissioner Poizner for Health Insurance Rescission Rules, Pans Schwarzenegger Administration for Failure to Regulate HMOs
11. GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Negative Pressure Wound Devices Draw FDA Notice, Advice 2Hangovers May Be Tougher for Migraine Sufferers 59737 1Drugs for Irritable Bowel Might Increase Cancer Risk 59736 1Drugs for Irritable Bowel Might Increase Cancer Risk 59736 2Evosys a Major Player in the Oracle E Business Suite Implementation Support and Consultancy Services Domain has Recently Been Awarded Oracles Certi 59733 1Evosys a Major Player in the Oracle E Business Suite Implementation Support and Consultancy Services Domain has Recently Been Awarded Oracles Certi 59733 2Evosys a Major Player in the Oracle E Business Suite Implementation Support and Consultancy Services Domain has Recently Been Awarded Oracles Certi 59733 3